



May 22, 2026

To,
The Manager
Listing Department,
The National Stock Exchange of India Limited
Exchange Plaza,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400051

Dear Sir/Madam,

Trading Symbol: ZOTA

Sub: Press Release on Audited Financial Results for the quarter and year ended March 31, 2026

With reference to the captioned subject; we, Zota Health Care Limited, are forwarding herewith enclosed a copy of press release on Audited Financial Results for the quarter and year ended March 31, 2026.

This is for your information and record.

Thanking you,

Yours faithfully,

For **Zota Health Care Limited**

Ashvin Variya
(Company Secretary & Compliance Officer)
Place: Surat

Encl.: Press Release

Registered Office:

Zota House, 2/896, Hira Modi Street,
Sagrampura, Surat-395002 Ph: +91 261 2331601
Email: info@zotahealthcare.com
Web: www.zotahealthcare.com

CIN: L24231GJ2000PLC038352

Zota Health Care Limited Reports Strong Revenue Growth of 83.86% YoY in FY26

FY26 Consolidated Revenues Grew to ₹ 53,865.75 lakhs: Consolidated EBITDA at ₹ 2,597.73 lakhs.

Davaindia Networks Expands to 2,579 Stores Nationwide

Surat, May 22, 2026: Zota Health Care Limited, one of the leading pharmaceutical company with an aim is to provide affordable, high-quality, generic medicines predominantly for chronic conditions, in addition to proprietary medicinal, OTC, ayurvedic, cosmetic, and nutraceutical products, announced financial results for the **fourth Quarter and full year ended 31st March 2026.**

Q4FY26 & FY26 Consolidated Financial Highlights:

Particulars (₹in Lakhs)	Quarter Ended			Year ended	
	Q4FY26	Q3FY26	Q4FY25	FY26	FY25
Export Sales (SEZ)	801.15	910.80	1,233.70	3,471.09	3,190.34
Davaindia Sales	13,147.71	11,479.27	6,281.66	41,741.47	18,621.40
Domestic Sales	1,919.70	1,577.32	1,771.10	6,794.29	6,341.50
Everyday Herbal Group	443.41	327.75	440.99	1,846.33	1,144.22
Others	5.56	-	-	12.57	-
Revenue from Operations	16317.53	14295.14	9,727.45	53,865.75	29,297.46
Gross Profit	10,355.82	8,617.82	4,940.00	32,468.90	15,567.13
Gross Margin %	63.46%	60.28%	50.78%	60.28%	53.13%
EBITDA	1191.18	127.57	346.80	2597.73	-366.51
EBITDA Margin%	7.30%	0.89%	3.57%	4.82%	-

As on 31st March 2026

Q4FY26 Business Highlights:

Particulars	Q4FY26			Q4FY25		
	COCO	FOFO	Total	COCO	FOFO	Total
Total No. of Davaindia stores*	1,656	923	2,579	852	730	1,582
Quarterly Footfall (lakhs)	39.80	15.27	55.07	19.00	11.90	30.90
Quarterly GMV (₹ lakhs)	9,324	4,711	14,035	4,297	3,385	7,682
Average wallets spend (₹)	₹ 235	₹ 309	-	₹ 227	₹ 285	-

As on 31st March 2026

FY26 Business Highlights:

Particulars	FY26			FY25		
	COCO	FOFO	Total	COCO	FOFO	Total
Total No. of Davaindia stores*	1,656	923	2,579	852	730	1,582
Yearly Footfall (lakhs)	126.69	55.78	182.47	55.11	42.56	97.67
Yearly GMV (₹ lakhs)	29,335	16,371	45,706	12,568	11,994	24,562
Average wallets spend (₹)	₹ 232	₹ 293	-	₹ 228	₹ 282	-

As on 31st March 2026

Key Operational & Financial Highlights:

- Consolidated Revenue from Operations stood at ₹ 53,865.75 lakhs in FY26, registering a significant YoY growth of 83.86% compared to ₹ 29,297.48 lakhs in FY25.
- Consolidated Gross Profit stood at ₹ 32,468.90 lakhs, as against ₹ 15,567.13 lakhs in FY25, reflecting a strong YoY increase of 108.57%, supported by improved scale. Gross Margin expanded by 714 bps to 60.28%.
- Consolidated EBITDA stood at ₹ 2,597.73 lakhs in FY26.
- Added 248 new stores during Q4FY26 with 218 COCO & 30 FOFO stores.
- Added 997 new stores during FY26 with 804 COCO & 193 FOFO stores which result in expansion of Davaindia network to 2,579 Stores Nationwide and makes it highest stores addition in the pharma retail segment in a single financial year.
- Zota Health Care Limited has appointed Mr. Akshay Kumar as the brand ambassador for the Company and its “UGO Generic” platform, operated through its wholly owned subsidiary, M/s KMHP Ventures Limited. UGO Generic aims to deliver high-quality, affordable medicines across India through a hybrid B2B and B2C model, leveraging owned stores and a targeted network of ~12.5 lakh retail pharmacies, strengthening nationwide reach and consumer trust.
- As part of its forward integration strategy, the Company, through Everyday Herbal Beauty Care Limited (EHBCL), has launched a new retail format, “All Day Stores” (ADS). The chain will offer a wide portfolio of private label products across personal care, household essentials, cosmetics, OTC, ayurvedic, surgical, and nutraceutical categories, with over 430 SKUs per store.
- The Company has further increased its stake in EHBCL to 87.78% through the acquisition of 1,18,00,000 equity shares via a rights issue, investing ₹19.47 crore at ₹16.50 per share. This step reinforces the Company’s backward integration strategy and enhances control over its expanding consumer business.

Commenting on the FY26 performance, Mr. Ketan Kumar Zota, Chairman, Zota Health Care Limited said,

“FY26 has been a defining year for Zota Health Care Limited, marked by strong execution and accelerated expansion across our Davaindia network. We have scaled our presence to 2,579 stores, alongside a significant increase in customer footfalls and GMV, reflecting growing consumer trust and deeper penetration of our affordable healthcare model.

During the year, we further strengthened our foundation through the successful completion of the ₹350 crore QIP and enhanced our stake in Everyday Herbal Beauty Care Limited, reinforcing our integrated business strategy. We also expanded into new growth avenues with the launch of ‘All Day Stores’ and ‘UGO Generic,’ aimed at building a comprehensive, value-driven healthcare and retail ecosystem across India

With a strengthened balance sheet, a rapidly expanding network, and the association of renowned personalities such as Mr. Akshay Kumar, Mr. Suniel Shetty, and Mr. M.S. Dhoni as our brand ambassadors, we enter FY27 with strong momentum. We remain committed to our long-term vision of reaching 5,000 Davaindia stores by FY29 and making high-quality, affordable healthcare accessible to every household in India”

About Zota Health Care Limited:

Zota Health Care Ltd. (Zota), listed on the NSE, has been a key player in the Indian healthcare industry since 2000. Headquartered in Surat, Zota's team of over 520 professionals drives its growth and strong market presence. The company specializes in the development, manufacturing, and marketing of high-quality pharmaceutical, ayurvedic, nutraceutical, and over-the-counter products.

Zota operates through three main divisions: marketing, export, and the retail pharmacy chain. In 2017, Zota launched Davaindia, a generic pharmacy chain offering over 2,000 SKUs of quality medicines. Davaindia's strategic business model ensures efficient management of the entire product life cycle through backward and forward integration.

Zota is renowned for its innovative Research and Development team, consistently investing in pioneering healthcare solutions, reinforcing its reputation in the industry. For more information, visit: www.zotahealthcare.com

For details please contact:

Ashvin Variya

Company Secretary & Compliance Officer
Zota Health Care Ltd
E: cszota@zotahealthcare.com

Siddesh Chawan

Ernst & Young LLP,
Investor Relations
E: Siddesh.Chawan@in.ey.com

Ajit Mishra

Ernst & Young LLP,
Investor Relations
E: Ajit.J.Mishra@in.ey.com

Disclaimer: Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political, or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. Zota Health Care Ltd. will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.